Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all
malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. …

Few diagnoses in medicine engender as much pessimism as the diagnosis of metastatic
cancer of an unknown primary site. Patients with this syndrome often have widespread …

Standard chemotherapy for disseminated germ-cell tumors includes a combination of cisplatin,
vinblastine, and bleomycin, but this regimen produces substantial neuromuscular toxicity. …

Neuroendocrine carcinomas of unknown primary site are uncommon, diverse tumors with
variable clinical behavior, predicted by tumor grade or differentiation. Most of these …

Objective: To determine whether very low doses of warfarin are useful in thrombosis
prophylaxis in patients with central venous catheters. Design: Patients at risk for thrombosis …

PURPOSE A phase II study of liposomal doxorubicin was conducted in patients with ovarian
cancer who failed to respond to platinum- and paclitaxel-based regimens. Liposomal …

PURPOSE: To evaluate response to single-agent rituximab in patients with indolent non-Hodgkin’s
lymphoma (NHL) and no previous systemic therapy, and the feasibility, toxicity, and …

Purpose Molecular tumor profiling is a promising diagnostic technique to determine the tissue
of origin in patients with carcinoma of unknown primary site (CUP). However, the clinical …

Four courses of PVP16B (cisplatin plus etoposide [VP-16] plus bleomycin) has been
standard chemotherapy for disseminated germ cell tumors at Indiana University and the …

Cancers of unknown primary site (CUPs) represent a heterogeneous group of metastatic
tumours for which a standardised diagnostic work-up fails to identify the site of origin at the time …